Cancer Screen is a genetic test that helps identify a person's inherited risk of developing certain types of cancer. Results are typically available in 15-20 days.
Know where you stand
The OncoScreen test includes a panel of 94 genes suspected to play a role in predisposing patients to cancer, including genes associated with common and rare cancers such as:
- Breast Cancer Lynch Syndrome
- Colorectal Cancer Prostate Cancer
- Melanoma Cancer Pancreatic Cancer
- Ovarian Cancer
The content selection of the panel is based on expert curations of the scientific literature. This includes genes listed in guidelines by medical societies including the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN).
Cancer is a genetic disease
It is caused by genetic changes to genes that control the way our cells function, especially how they grow and divide. While many cancer-causing genetic changes (mutations) can be acquired during one’s lifetime, some of the genetic changes can be inherited from our parents.
Genetic testing from a saliva sample may identify inherited genetic mutations that can increase a person’s lifetime risk for certain types of cancer.
Why is genetic testing for cancer predisposition important?.
Genetic testing can help identify genetic mutations that can increase your risk for certain cancers. This can help your healthcare provider:
Modify the frequency and initial age of mammogram/breast MRI, colonoscopy, prostate cancer screening or other surveillance strategies.
Identify other at-risk family members.
Discuss prevention options such as chemoprevention, prophylactic mastectomy, colectomy, prophylactic oophorectomy or other risk reducing interventions.
Who is eligible to be tested?
According to the national comprehensive cancer network genetic testing for hereditary cancer should be considered if a patient or their family members meet any of the following criteria:
- 3 or more cancer on the same side of the family.
- 2 or more primary cancers in the same person.
- Early diagnosis (≤ 50 yrs. old) of breast, colorectal or uterine cancer.
- Multiple Cancers especially if diagnosed before age of 50yrs.
- Of Ashkenazi Jewish descent and history of breast, ovarian or pancreatic cancer at any age.
- A blood relative with male breast cancer.
- 10 or more colorectal polyps in a person’s life time.
American Society of Clinical Oncology (ASCO)
ASCO recommends that genetic testing be offered to individuals with suspected inherited (genetic) cancer risk in situations where test results can be interpreted, and when they affect medical management of the patients. Adapted from Journal of clinical Oncology 2015.
AIP, ALK, APC, ATM, BAP1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, BUB1B, CDC73, CDH1, CDK4, CDKN1C, CDKN2A, CEBPA, CEP57,CHEK2,CYLD, DDB2, DICER1, DIS3L2, EGFR, EPCAM, ERCC2, ERCC3, ERCC4, ERCC5, EXT1, EXT2, EZH2, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI,FANCL, FANCM, FH, FLCN, GATA2, GPC3, HNF1A, HRAS, KIT, MAX, MEN1, MET, MLH1, MSH2, MSH6, MUTYH, NBN, NF1, NF2, NSD1, PALB2, PHOX2B , PMS1, PMS2 ,PRF1 , PRKAR1A , PTCH1 , PTEN , RAD51C , RAD51D , RB1 , RECQL4 , RET , RHBDF2 , RUNX1 , SBDS , SDHAF2 , SDHB , SDHC , SDHD , SLX4, SMAD4, SMARCB1, STK11,SUFU, TMEM127, TP53, TSC1, TSC2, VHL, WRN, WT1, XPA, and XPC
It takes a few simple steps to generate your personalized patient results in 15-20 business days.
Cancer sample report
OncoScreen-BHARATH_sample_report